These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 19160441)

  • 61. Statistical evaluation of physiological variability of rifampicin in fixed dose combinations.
    Panchagnula R; Parmar J; Kaur K; Singh I; Bade SR; Ashokraj Y
    Int J Pharm; 2006 Apr; 313(1-2):5-13. PubMed ID: 16517107
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Recent bioequivalence studies on fixed-dose combination anti-tuberculosis drug formulations available on the global market.
    Pillai G; Fourie PB; Padayatchi N; Onyebujoh PC; McIlleron H; Smith PJ; Gabriels G
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S309-16; discussion S317-21. PubMed ID: 10593710
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Rifampicin bioavailability: a review of its pharmacology and the chemotherapeutic necessity for ensuring optimal absorption.
    Ellard GA; Fourie PB
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S301-8; discussion S317-21. PubMed ID: 10593709
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Influence of Drug Properties and Formulation on In Vitro Drug Release and Biowaiver Regulation of Oral Extended Release Dosage Forms.
    Lin Z; Zhou D; Hoag S; Qiu Y
    AAPS J; 2016 Mar; 18(2):333-45. PubMed ID: 26769249
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Commonality between BCS and TCS.
    Shah VP; Rădulescu FŞ; Miron DS; Yacobi A
    Int J Pharm; 2016 Jul; 509(1-2):35-40. PubMed ID: 27208656
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: verapamil hydrochloride, propranolol hydrochloride, and atenolol.
    Vogelpoel H; Welink J; Amidon GL; Junginger HE; Midha KK; Möller H; Olling M; Shah VP; Barends DM
    J Pharm Sci; 2004 Aug; 93(8):1945-56. PubMed ID: 15236445
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Alginate-based oral drug delivery system for tuberculosis: pharmacokinetics and therapeutic effects.
    Qurrat-ul-Ain ; Sharma S; Khuller GK; Garg SK
    J Antimicrob Chemother; 2003 Apr; 51(4):931-8. PubMed ID: 12654730
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Effect of activated charcoal on rifampicin absorption in man.
    Orisakwe OE; Dioka CE; Okpogba AN; Orish CN; Ofoefule SI
    Tokai J Exp Clin Med; 1996 Feb; 21(1):51-4. PubMed ID: 9239805
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Comparative bioavailability of three different preparations of rifampicin.
    Pähkla R; Lambert J; Ansko P; Winstanley P; Davies PD; Kiivet RA
    J Clin Pharm Ther; 1999 Jun; 24(3):219-25. PubMed ID: 10438182
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A pilot stability study on four-drug fixed-dose combination anti-tuberculosis products.
    Singh S; Mohan B
    Int J Tuberc Lung Dis; 2003 Mar; 7(3):298-303. PubMed ID: 12661847
    [TBL] [Abstract][Full Text] [Related]  

  • 71. In vitro analysis of rifampicin and its effect on quality control tests of rifampicin containing dosage forms.
    Agrawal S; Panchagnula R
    Pharmazie; 2004 Oct; 59(10):775-81. PubMed ID: 15544056
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Lack of effect of fluconazole on the pharmacokinetics of rifampicin in AIDS patients.
    Jaruratanasirikul S; Kleepkaew A
    J Antimicrob Chemother; 1996 Nov; 38(5):877-80. PubMed ID: 8961059
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Dissolution test as a surrogate for quality evaluation of rifampicin containing fixed dose combination formulations.
    Agrawal S; Panchagnula R
    Int J Pharm; 2004 Dec; 287(1-2):97-112. PubMed ID: 15541917
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Novel anti-tuberculosis FDC formulations without reduced bioavailability of rifampicin: from concept to market.
    Singh S; Mariappan TT; Bhutani H
    Int J Tuberc Lung Dis; 2005 Jun; 9(6):701-2. PubMed ID: 15971403
    [No Abstract]   [Full Text] [Related]  

  • 75. Pharmaceutical formulation of a fixed-dose anti-tuberculosis combination.
    Danckwerts MP; Ebrahim S; Pillay V
    Int J Tuberc Lung Dis; 2003 Mar; 7(3):289-97. PubMed ID: 12661846
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: chloroquine phosphate, chloroquine sulfate, and chloroquine hydrochloride.
    Verbeeck RK; Junginger HE; Midha KK; Shah VP; Barends DM
    J Pharm Sci; 2005 Jul; 94(7):1389-95. PubMed ID: 15920763
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The development of a standardised screening protocol for the in vivo assessment of rifampicin bioavailability.
    McIlleron H; Gabriels G; Smith PJ; Fourie PB; Ellard GA
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S329-35; discussion S351-2. PubMed ID: 10593713
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Regulatory Perspectives on Strength-Dependent Dissolution Profiles and Biowaiver Approaches for Immediate Release (IR) Oral Tablets in New Drug Applications.
    Suarez-Sharp S; Delvadia PR; Dorantes A; Duan J; Externbrink A; Gao Z; Ghosh T; Miksinski SP; Seo P
    AAPS J; 2016 May; 18(3):578-88. PubMed ID: 26928450
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Risk analysis in bioequivalence and biowaiver decisions.
    Kubbinga M; Langguth P; Barends D
    Biopharm Drug Dispos; 2013 Jul; 34(5):254-61. PubMed ID: 23280474
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Biopharmaceutics classification system: the scientific basis for biowaiver extensions.
    Yu LX; Amidon GL; Polli JE; Zhao H; Mehta MU; Conner DP; Shah VP; Lesko LJ; Chen ML; Lee VH; Hussain AS
    Pharm Res; 2002 Jul; 19(7):921-5. PubMed ID: 12180542
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.